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Background: In SMILE-4 (the Survival of Myocardial Infarction Long-term Evaluation 
4 study), zofenopril + acetylsalicylic acid (ASA) was superior to ramipril + ASA in reducing 
the occurrence of major cardiovascular events in patients with left ventricular dysfunction 
following acute myocardial infarction. The present post hoc analysis was performed to compare 
the cost-effectiveness of zofenopril and ramipril.
Methods: In total, 771 patients with left ventricular dysfunction and acute myocardial 
infarction were randomized in a double-blind manner to receive zofenopril 60 mg/day (n = 389) 
or ramipril 10 mg/day (n = 382) + ASA 100 mg/day and were followed up for one year. The 
primary study endpoint was the one-year combined occurrence of death or hospitalization for 
cardiovascular causes. The economic analysis was based on evaluation of cost of medications 
and hospitalizations and was applied to the intention-to-treat population (n = 716). Cost data 
were drawn from the National Health Service databases of the European countries participating 
in the study. The incremental cost-effectiveness ratio was used to quantify the cost per event 
prevented with zofenopril versus ramipril.
Results: Zofenopril significantly (P = 0.028) reduced the risk of the primary study endpoint by 
30% as compared with ramipril (95% confidence interval, 4%–49%). The number needed to treat 
to prevent a major cardiovascular event with zofenopril was 13 less than with ramipril. The cost 
of drug therapies was higher with zofenopril (328.78 Euros per patient per year, n = 365) than 
with ramipril (165.12 Euros per patient per year, n = 351). The cost related to the occurrence 
of major cardiovascular events requiring hospitalization averaged 4983.64 Euros for zofenopril 
and 4850.01 Euros for ramipril. The incremental cost-effectiveness ratio for zofenopril versus 
ramipril was 2125.45 Euros per event prevented (worst and best case scenario in the sensitivity 
analysis was 3590.09 and 3243.96 Euros, respectively).
Conclusion: Zofenopril is a viable and cost-effective treatment for managing patients with 
left ventricular dysfunction after acute myocardial infarction.
Keywords: acute myocardial infarction, left ventricular dysfunction, angiotensin-converting 
enzyme inhibitors, zofenopril, ramipril, acetylsalicylic acid, cost-effectiveness
Introduction
The results of major clinical trials clearly demonstrate that angiotensin-converting 
enzyme (ACE) inhibitors effectively prevent morbidity and mortality of patients after 
acute myocardial infarction (AMI), particularly if associated with left ventricular 
dysfunction (LVD).1–5 Thus, practice guidelines now recommend that all AMI 
patients receive treatment with an ACE inhibitor in combination with a beta-blocker, 
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a lipid-lowering agent, and acetylsalicylic acid (ASA), unless 
a contraindication exists.6–9
In addition, several large-scale, randomized, prospective 
studies have evaluated the cost-effectiveness of ACE 
inhibitors in the treatment of AMI and heart failure. The 
results of such economic analyses unanimously indicate that 
ACE inhibitors are cost-effective when used to treat patients 
after AMI,10–13 and argue for the widest possible use of ACE 
inhibitors in this setting.14–17
Zofenopril is a sulfhydryl-containing lipophilic ACE 
inhibitor with ancillary and cardioprotective properties.18–21 
Following extensive evidence of its efficacy and safety derived 
from the randomized controlled studies of the SMILE (Survival 
of Myocardial Infarction Long-term Evaluation) program, 
zofenopril is currently indicated for treatment initiated within 
the first 24 hours in patients with AMI with or without signs and 
symptoms of heart failure, who are hemodynamically stable 
and have not received thrombolytic therapy.22,23 Recently, the 
SMILE-4 study demonstrated that the efficacy of zofenopril 
associated with ASA is superior to that of ramipril + ASA in 
patients with LVD following AMI, in terms of prevention of 
major cardiovascular outcomes.24
Although the clinical efficacy of zofenopril is clear from 
the SMILE studies, the question remains as to whether the 
added benefit of zofenopril is worth the added cost. For this 
reason, we undertook a post hoc cost-effectiveness analysis 
to compare the cost-effectiveness of zofenopril and ramipril 
in patients with LVD after an AMI.
Materials and methods
Clinical trial
The SMILE-4 trial was a large multicenter, randomized, 
prospective study, the methodology and results of which are 
reported in detail elsewhere.24 Briefly, male and nonpregnant 
female patients aged 18–85 years with a confirmed diagnosis 
of ST or non-ST segment elevation myocardial infarction in 
the 24 hours preceding enrollment (not treated with primary 
percutaneous transluminal coronary angioplasty, treated or 
not with thrombolysis and recommended pharmacologic 
treatment) and with clinical and/or echocardiographic 
evidence of LVD (Killip class . 1, plus a third heart sound, 
pulmonary congestion on chest x-ray, and/or a left ventricular 
ejection fraction , 45%) were enrolled in 79 hospitals in 
eight European countries.
Eligible patients entered a four-day, open-label phase 
during which zofenopril was administered to all patients 
according to an uptitration scheme. On days 1 and 2, patients 
received zofenopril 7.5 mg twice daily + an evening dose 
of ASA 100 mg. On days 3 and 4, the zofenopril dose was 
doubled (to 15 mg twice daily) while the dose of ASA 
remained unchanged. On day 5, patients were randomized 
1:1 in a double-blind manner to receive zofenopril 30 mg 
twice daily + ASA 100 mg once daily or ramipril 5 mg twice 
daily + ASA 100 mg once daily for 12 months. The study 
medications were administered in combination with standard 
recom mended treatments for AMI, excluding ACE inhibitors, 
angiotensin receptor blockers, and antiplatelet drugs other 
than ASA, clopidogrel, or ticlopidine. Concomitant chronic 
anticoagulant treatment was allowed in the acute phase of 
myocardial infarction and in case of a specific indication, or 
in patients who reached a study endpoint. Patients were seen 
at enrollment, at randomization (5 days after enrollment) 
and after months 1, 6, and 12. Blood pressure and heart rate 
were measured, an echocardiogram was performed, blood 
samples were drawn (centralized estimation of N-terminal 
pro-brain natriuretic peptide), and occurrence of concomitant 
diseases, adverse events, use of concomitant medications, and 
compliance with the study drugs were checked at each study 
visit. A physical examination, a 12-lead electrocardiogram, 
and laboratory tests (hematology, clinical chemistry, and 
urinalysis) were performed at entry, at randomization, and 
at study end.
Cost analysis
The initial aim of the cost analysis was to investigate whether 
use of zofenopril might be cost-neutral or cost-saving. Only 
drug and hospitalization or event costs were included in this 
analysis. The perspective adopted for the study was that of a 
third-party payer, ie, the individual national health services of 
the countries participating in the study. A reference cost was 
obtained by averaging costs for each country and presenting 
them in 2012 Euros.
Medications
The unit costs of the study drugs (zofenopril, ramipril, 
and ASA) were derived from the national pharmaceutical 
formulary for each country, using the reimbursement price 
for the generic drug as reference. The cost of zofenopril was 
estimated at 0.80 Euros per day using the 28-tablet pack, that 
of ramipril 0.34 Euros per day using the 14-tablet pack, and 
that of ASA 0.10 Euro per day using the 30-tablet pack.
Events
The unit costs for post-AMI events were calculated 
considering a Diagnosis-Related Group code. Information 
on costs for each type of event and for each individual 
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country was collected and averaged to obtain a reference 
cost.25 Because the reference payment list did not refer to 
a decline in left ventricular ejection fraction . 15%, this 
cost was conservatively estimated as one-third of the cost 
of a hospitalization for symptomatic heart failure. The 
assumption underlying this choice was that a patient with 
such clinical worsening will experience at least one admission 
for symptomatic heart failure in the next three years, with no 
other major cardiovascular events.
Statistical analysis
The economic evaluation of SMILE-4 was based on 
estimation of the costs of drugs and events, and on cost-
effectiveness analysis. The clinical benefits were also 
calculated from endpoints used in the trial, and converted to 
the “number needed to treat”, an expression of the number 
of patients who must be treated with one drug to prevent one 
adverse event. The calculation was done as follows:
 1/(Relative frequency of major cardiovascular events  
   with zofenopril − Relative frequency of major 
   cardiovascular events with ramipril).26
The analysis was carried out in the intention-to-treat pop-
ulation, as for the clinical outcomes in the original study,24 ie, 
in patients treated with at least one dose of study medication 
and documenting at least once, the measure of the primary 
efficacy assessment, even in the event of protocol violation 
or premature withdrawal from the study.
The economic effects were established by undertaking 
an incremental cost-effectiveness analysis. The results of the 
analysis were expressed by means of an incremental cost-
effectiveness ratio (ICER), and calculated as incremental 
drug costs divided by incremental effects. The difference in 
the rate of occurrence of major cardiovascular events between 
the two study groups (first occurrence of cardiovascular 
death or hospitalization for cardiovascular causes, including 
congestive heart failure, acute myocardial infarction, angina, 
revascularization, or a decline in left ventricular ejection 
fraction . 15%) was used as the incremental effect. This was 
the original primary study endpoint for the main study.24
The ICER was calculated by the following equation:
Incremental cost-effectiveness ratio  
 =  (Cost of zofenopril treatment for 1 year − Cost of 
ramipril treatment for 1 year)/(Relative frequency of 
major cardiovascular events with zofenopril over one 
year − Relative frequency of major cardiovascular 
events with ramipril over one year).27–29
The cost-effectiveness study was done according 
to a base-case analysis supplemented with a sensitivity 
analysis.27,30 In the base-case analysis, exclusively average 
values of the model input parameters were used. In the 
sensitivity analysis, we assessed the impact of increasing 
the price of zofenopril by 20% and decreasing the price of 
ramipril by 20% on the cost-effectiveness of the intervention 
according to a deterministic one-way analytical approach. 
Uncertainty in the point estimate of the ICER was also 
investigated by varying the event size while costs remained 
the same or by combining changes in unit costs and 
event size, in order to obtain a worst/best case scenario 
analysis.
Results
Clinical efficacy
The present study analyzed the 716 patients included in 
the intention-to-treat analysis of the main SMILE-4 study 
(365 treated with zofenopril 60 mg and 351 with ramipril 
10 mg). No significant differences in baseline patient 
de mographic and clinical characteristics were observed 
between the treatment groups (Table 1), with the only 
exception being the proportion of patients with arterial 
hypertension (P = 0.033), previous percutaneous transluminal 
coronary angioplasty (P = 0.044), and impaired left 
ventricular ejection fraction (P = 0.009). Further details are 
reported in the main study publication.24
During the 12 months of double-blind, randomized 
treatment, major cardiovascular events occurred in 105 of 
the 365 patients treated with zofenopril (29%) and in 128 of 
the 351 patients treated with ramipril (37%), with a 30% 
significantly (P = 0.028) lower risk of achieving the combined 
endpoint (95% confidence interval, 4%–49%) in zofenopril-
treated patients24 (Table 2). This figure resulted in a number 
needed to treat of 13, indicating that one major cardiovascular 
event could be prevented with zofenopril by treating 13 fewer 
patients than with ramipril.
Cost effectiveness
The average cost of drug treatment per patient per year was 
328.78 Euros for zofenopril + ASA and 165.12 Euros for 
ramipril + ASA. The cost related to occurrence of major 
cardiovascular events averaged 4983.64 Euros for zofenopril 
and 4850.01 Euros for ramipril (Table 3). When the two study 
groups were pooled together, the average estimated cost per 
event was 4910.23 Euros. Treatment with zofenopril yielded 
an ICER of 2125.45 Euros for any additional event prevented 
compared with ramipril.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
319
Cost-effectiveness of zofenopril in myocardial infarction
ClinicoEconomics and Outcomes Research 2013:5
Table 2 Absolute and relative frequency (%) for the various 
components of the SMILE-4 primary study endpoint (hospitalization 
for cardiovascular causes or cardiovascular mortality) in the 
intention-to-treat population of SMILE-424 (n = 716)
Zofenopril 
(n = 365)
Ramipril 
(n = 351)
Hospitalization for cardiovascular causes (n, %)
 Congestive heart failure 4 (1.1) 7 (2.0)
 Acute myocardial infarction 13 (3.6) 16 (4.6)
 Angina pectoris 20 (5.5) 22 (6.3)
  Decline in left ventricular ejection 
fraction . 15%
15 (4.1) 28 (8.0)
 Revascularization 25 (6.8) 32 (9.1)
 Other causes 11 (3.0) 12 (3.4)
Total 88 (24.1) 117 (33.3)
 Unadjusted OR (95% CI) 0.64 (0.46–0.88)
  P value 0.006
 Adjusted OR (95% CI) 0.65 (0.46–0.91)
  P value 0.012
Cardiovascular death (n, %)
 Congestive heart failure 4 (1.1) 2 (0.6)
 Acute myocardial infarction 6 (1.6) 1 (0.3)
 Sudden death 6 (1.6) 6 (1.7)
 Cardiac rupture 1 (0.3) 1 (0.3)
 Stroke 0 (0.0) 1 (0.3)
Total 17 (4.7) 11 (3.1)
 Unadjusted OR (95% CI) 1.51 (0.70–3.27)
  P value 0.293
 Adjusted OR (95% CI) 1.18 (0.51–2.70)
  P value 0.704
Overall major cardiovascular 
events (n, %)
105 (28.8) 128 (36.5)
 Unadjusted OR (95% CI) 0.70 (0.51–0.96)
  P value 0.028
 Adjusted OR (95% CI) 0.68 (0.49–0.95)
  P value 0.024
Notes: Unadjusted and adjusted odds ratio and corresponding confidence intervals 
with P values are also reported. OR adjustment by age, gender, glomerular filtration 
rate, left ventricular ejection fraction, Killip class, revascularization, diabetes, 
metabolic syndrome, hypercholesterolemia, low high-density lipoprotein, ST versus 
non-ST elevation myocardial infarction, N-terminal pro-brain natriuretic peptide, 
and heart rate.
Abbreviations: CI, confidence interval; OR, odds ratio.
Table 1 Baseline demographic and clinical characteristics of the 
intention-to-treat population in SMILE-424 (n = 716)
Characteristics Zofenopril 
(n = 365)
Ramipril 
(n = 351)
Age (years, mean ± SD) 61 ± 11 61 ± 11
Males (n, %) 268 (73) 276 (79)
BMI (kg/m2, mean ± SD) 28 ± 4 28 ± 4
Diabetes mellitus (n, %) 68 (19) 63 (19)
Treated hypercholesterolemia (n, %) 68 (19) 72 (21)
Treated arterial hypertension (n, %) 237 (65) 200 (57)
Relevant concomitant treatments (n, %)
 ACE inhibitors 13 (4) 3 (1)
 Angiotensin II antagonists 4 (1) 1 (1)
 Beta-blockers 199 (55) 177 (50)
 Alpha-blockers 24 (7) 28 (8)
 Calcium antagonists 8 (2) 13 (4)
 Diuretics 73 (20) 74 (21)
 Digoxin – 3 (1)
 Nitrates 128 (35) 117 (33)
 Antiarrhythmic drugs 14 (4) 9 (3)
 Statins 217 (59) 200 (57)
 Other lipid-lowering drugs 15 (4) 17 (5)
 Other cardiovascular drugs 47 (13) 32 (9)
Atrial fibrillation (n, %) 7 (2) 2 (1)
Peripheral arterial occlusive disease (n, %) 17 (5) 18 (5)
Previous myocardial infarction (n, %) 72 (20) 61 (18)
Angina pectoris (n, %) 140 (39) 123 (35)
Prior PTCA (n, %) 26 (7) 13 (4)
Prior CABG (n, %) 6 (2) 6 (2)
Congestive heart failure (n, %) 24 (7) 25 (7)
PTCA performed at entry (n, %) 115 (31) 109 (31)
Thrombolytic therapy performed 
at entry (n, %)
141 (39) 134 (38)
LVEF # 40% (n, %) 151 (41) 111 (32)
SBP (mmHg, mean ± SD) 139 ± 24 140 ± 24
DBP (mmHg, mean ± SD) 83 ± 14 83 ± 13
HR (beats per minute, mean ± SD) 81 ± 17 79 ± 16
Abbreviations: ACE, angiotensin-converting enzyme; SD, standard deviation; 
BMI, body mass index; PTCA, percutaneous transluminal coronary angioplasty; 
CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.
Sensitivity analysis
The overall result was not modified by applying sensitivity 
analysis. A first analysis varying the price of zofenopril 
and ramipril returned an ICER of 3408.26 Euros. When 
the lower limit of the 95% confidence interval for the event 
rate was used, the ICER was 2238.82 Euros, whereas the 
corresponding figure was 2022.96 Euros when the upper 
limit was selected. The worst case scenario, determined by 
combination of the modified drug costs and the lower limit 
for event rate, gave an ICER of 3590.09 Euros, while the best 
case scenario returned an ICER of 3243.96 Euros.
Discussion
Economic analysis of drug treatment is increasingly 
incorporated routinely into many clinical trials, because 
this type of information, in conjunction with the usual 
safety and efficacy data, is becoming more important to 
pharmaceutical companies, regulatory authorities, third-
party payers, and end-users. The present study examined 
vis-à-vis the cost-effectiveness of two ACE inhibitors 
used widely in post-AMI patients with LVD, ie, zofenopril 
and ramipril. According to our findings, treatment with 
zofenopril costs between 2023 Euros (best case sensitivity 
analysis) and 3590 Euros (worst case analysis) to generate 
any additional event prevented compared with ramipril. This 
cost-effectiveness threshold is within the range of health 
care programs currently funded in developed countries 
which usually consider a threshold , 20,000–40,000 USD 
(about 15,000–30,000 Euros) as being compatible with a 
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highly cost-effective treatment in the management of heart 
disease.10,31,32
As summarized in Table 4, the cost-effectiveness ratio 
calculated for zofenopril also appears favorable compared 
with many other strategies for the management of AMI 
or stable angina, including drug treatment, thrombolysis, 
percutaneous coronary intervention, or coronary artery 
bypass grafting.10,13,31–36 In addition, the estimated cost-
effectiveness of zofenopril compares well with that of other 
ACE inhibitors, although such a comparison, discussed in the 
next paragraphs, has limitations because the model used varies 
between studies. A recently published economic analysis of 
diverse cardiologic interventions from 2000 to 2010 in 
England and Wales showed reasonable cost-effectiveness 
for ACE inhibitors, ranging from approximately 2500 Euros 
up to 4400 Euros for secondary prevention in heart failure 
patients.13 Concerning a comparison with specific ACE 
inhibitors, the incremental cost per life-year gained using 
prophylactic captopril in survivors of AMI with a reduced 
left ventricular ejection fraction in the SAVE study ranged 
between 800 and 8000 Euros, depending on age, country, 
and time period considered.37–40 In the GISSI-3 trial, which 
assessed the efficacy of early (within 24 hours) treatment with 
lisinopril in unselected patients with AMI, the comparative 
cost-effectiveness ratio for use of lisinopril, expressed as 
cost per additional survivors among patients randomized 
to receive lisinopril, was approximately 1600 Euros per life 
saved.41 In the TRACE study, the ICER of treating post-AMI 
patients with LVD with trandolapril rather than with placebo 
was estimated at approximately 900 Euros.15 In the patients 
with stable coronary artery disease included in EUROPA, 
the median incremental cost of perindopril for each quality-
adjusted life-year gained was estimated to be about 12,000 
Euros.17
The cost-effectiveness of ramipril versus placebo has 
been estimated in two large, randomized, prospective studies, 
ie, HOPE and AIRE. In the HOPE study, which recruited 
patients with an increased risk of cardiovascular events, 
the estimated cost-effectiveness of ramipril ranged between 
4000 and 14,000 Euros per life-year gained at five years, 
depending on the various local economic analyses, with 
costs consistently decreasing for lifetime treatment.42–48 In the 
USA and Canada, the majority of patients in the HOPE study 
Table 3 Unit and overall costs for treating each single event in SMILE-4
Outcome Cost per event per 
patient (Euros)
Zofenopril (n = 365) Ramipril (n = 351)
Events (n) Total cost (Euros) Events (n) Total cost (Euros)
Congestive heart failure 3425.51 4 13,702.04 7 23,978.57
Acute myocardial infarction 4019.04 13 52,247.52 16 64,304.64
Angina pectoris 2642.24 20 52,844.80 22 58,129.28
Decline in LVEF . 15% 1141.84 15 17,127.55 28 31,971.43
Revascularization 10,993.14 25 274,828.38 32 351,780.32
Other causes 3650.20 11 40,152.20 12 43,802.40
Death 4257.64 17 72,379.88 11 46,834.04
Overall cost 523,282.37 620,800.68
Average cost per patient 4983.64 4850.01
Note: Number of occurrences for each outcome is also indicated.
Abbreviation: LVEF, left ventricular ejection fraction.
Table 4 Cost-effectiveness of various interventions versus 
standard care in the management of acute myocardial infarction 
Strategy Cost effectiveness 
(Euros/YLS or 
QALYS)
Drugs
  Medical treatment alone in patients 
with multivessel CAD and normal EF33
7000
  β-blocker in high risk post-AMI patients10 2800
  β-blocker in low risk post-AMI patients10 15,600
  Captopril in post-AMI patients with 
EF # 40%10
21,900
Reperfusion therapy
 Thrombolysis13 1750
  Streptokinase in elderly ($75 years) 
AMI patients10
21,400
 Primary PTCA13,33 8800–15,400
  Primary PTCA in patients with large 
infarct size10
34,500
  PTCA in patients with multivessel CAD 
and normal EF33
15,400
 Non-elective PTCA with stenting36 14,500–33,900
  PTCA in addition to optimal medical 
therapy in presence of stable angina35
24,805
  CABG in patients with multivessel CAD 
and normal EF (CABG)33
14,100
CCU in patients with highly probable 
($50%) MI10
27,000
Note: The strategy, along with its cost-effectiveness, expressed in 2012 Euros 
per year life saved or quality-adjusted life-year is reported.
Abbreviations: AMI, acute myocardial infarction; CABG, coronary artery bypass 
graft; CCU, coronary care unit; CAD, coronary artery disease; EF, ejection fraction; 
PTCA, percutaneous transluminal coronary angioplasty; YLS, year life saved; 
MI, myocardial infarction; QALYs, quality-adjusted life-years.
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fell into a cost-effectiveness situation with an ICER , 8000 
Euros per primary event saved.16 In the AIRE study, the 
incremental cost of ramipril per life-year gained in patients 
with heart failure following AMI ranged between 1300 and 
3900 Euros after 3.8 years of follow-up in three European 
subanalyses.49–51
There are a number of limitations to our economic 
analysis. First, and more importantly, this cost analysis was 
conducted after the randomized trial had been completed. 
Thus, a limited amount of variables were available to enable 
us to measure health care utilization in detail. Although 
some indicators useful for a more indepth pharmacoeco-
nomic analysis, such as quality of life or life-years gained, 
were not assessed, hospitalizations and related causes were 
recorded prospectively at the time of the original study and 
were classified correctly using an event-driven system, ie, 
Diagnosis-Related Group code.
Second, a third-party payer perspective as an integrated 
public health care system where all costs are recorded was 
chosen for the cost analysis. Although it is suggested that a 
societal perspective be considered, it is recognized that use of 
other perspectives is acceptable and might be more appropriate 
in some cases.28,29 Unfortunately, we were forced to consider 
costs from the perspective of the health care system because 
of the limitations of the data available to us.
Third, one cost item (decline in left ventricular ejection 
fraction) was missing, but the assumption made does not 
appear to have had a major impact on the positive cost-benefit 
ratio of use of zofenopril versus ramipril. In fact, the number 
of patients with a significant reduction in left ventricular 
ejection fraction was larger in the ramipril-treated group, 
so the cost-benefit ratio of zofenopril would have been still 
in favor of this drug, even if the actual number of hospital 
admissions per year was significantly different from the 
number assumed in the calculations.
Fourth, our economic analysis applies to a relatively 
limited time horizon (one year), and we do not know whether 
the cost-effectiveness ratio remains favorable even if clini-
cal benefit is assumed to stop at the end of the clinical trial 
follow-up period. Whilst this lack of continuing effect is 
implausible, any quantification of benefit beyond this period 
is not possible, and we cannot address the issue of how long 
zofenopril should be taken.
Fifth, in common with most economic analyses of this 
type, cost calculations were limited to the medical costs of 
both treatments, and nonmedical costs, direct and indirect, 
such as those due to productivity losses, were not evaluated 
or taken into account. In addition, due to the perspective and 
time span of the observation, we did not assess direct costs, 
such as rehabilitation and long-term care.
Finally, we did not compare the cost-effectiveness 
of zofenopril versus placebo, but versus another ACE 
inhibitor. However, zofenopril was cost-saving compared 
with ramipril, a drug already proven to be cost-effective 
in patients at high risk of cardiovascular disease, including 
post-AMI patients.42–51
Conclusion
The use of zofenopril in patients with LVD following AMI 
is not only associated with a 30% reduction in the risk of 
major cardiovascular events over one year, but also appears 
to be a good strategy from a health economics perspective. 
The incremental cost of zofenopril in the SMILE-4 Study 
was lower than the apparent threshold used to define a 
cardiac treatment as highly cost-effective (15,000–30,000 
Euros). In addition, the cost-effectiveness of zofenopril in 
our study (just over 2000 Euros) compares favorably with 
that observed for ramipril in high cardiovascular risk and 
post-AMI patients (1300–14,000 Euros) and for other ACE 
inhibitors, such as captopril (800–8000 Euros), lisinopril 
(1600 Euros), trandolapril (900 Euros), and perindopril 
(12,000 Euros). Therefore, our results place zofenopril among 
the viable and cost-effective options for treating post-AMI 
patients with LVD.
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